|
|
|
30 Sep 2008 |
Once-yearly Aclasta (R) approved in EU to treat osteoporosis in men and to reduce risk of new fractures following hip fracture both in men and postmenopausal women
|
|
30 Sep 2008 |
Indevus Announces Initiation of Phase III Clinical Trial of Octreotide Implant for Acromegaly
|
|
29 Sep 2008 |
Takeda Submitted a New Drug Application in Japan for Actos(R) Orally Disintegrating Tablets
|
|
29 Sep 2008 |
Takeda Submitted a New Drug Application for Alogliptin in Japan for Treatment of Type 2 Diabetes
|
|
28 Sep 2008 |
Merck KGaA’s Kuvan(R) Recommended for European Approval
|
|
28 Sep 2008 |
Indevus and FDA Agree on Path Forward for NEBIDO(R)
|
|
25 Sep 2008 |
Merck & Co., Inc. and Japan Tobacco Inc. Sign Licensing Agreement for Novel Osteoanabolic Drug Candidate to Treat Osteoporosis
|
|
25 Sep 2008 |
Array BioPharma Presents Positive Preclinical Data on Its Glucokinase Activators in Type 2 Diabetes
|
|
25 Sep 2008 |
Hollis-Eden Pharmaceuticals Presents Positive Updated Data from Phase I/II Clinical Trial with TRIOLEX(TM) in Obese Insulin Resistant Subjects
|
|
25 Sep 2008 |
Recent research shows significant benefits in acute ischaemic stroke with Actilyse(R) beyond currently approved three hour treatment window
|
|
24 Sep 2008 |
Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
|
|
24 Sep 2008 |
Metabasis Therapeutics Announces Initiation of a Clinical Trial for MB07803, Its Novel Product Candidate for the Treatment of Type 2 Diabetes
|
|
24 Sep 2008 |
Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
|
|
24 Sep 2008 |
Athersys Announces Update On ATHX-105 Development Plans and Results of Recent Clinical Studies
|
|
22 Sep 2008 |
Protalix BioTherapeutics Provides Enrollment Update for the Phase III Clinical Trial of prGCD
|
|
22 Sep 2008 |
Akesis Pharmaceuticals Expands Preclinical Safety Program for Lead Product
|
|
21 Sep 2008 |
Unigene Reports on Design of Clinical Program for Oral Calcitonin
|
|
18 Sep 2008 |
Vivendy's Treatment for Morbus Morquio (MPS IVA) Granted Orphan Drug Designation by FDA
|
|
17 Sep 2008 |
MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
|
|
17 Sep 2008 |
Sirtris Completes Exclusive License to Harvard’s SIRT3-Based Intellectual Property
|
|
16 Sep 2008 |
Takeda Milestone Payment
|
|
16 Sep 2008 |
Denosumab Osteoporosis Trial Finds Patients Transitioned from Alendronate (Fosamax(R)) to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density versus Those Continuing on Alendronate
|
|
16 Sep 2008 |
ENOBIA PHARMA PRESENTS PRECLINICAL DATA SHOWING ENB-0040 SIGNIFICANTLY IMPROVED SURVIVAL AND HEALED SKELETAL MANIFESTATIONS OF SEVERE HYPOPHOSPHATASIA IN MICE
|
|
16 Sep 2008 |
Positive Interim Data from Phase 2 Study of NPSP558 (Parathyroid Hormone 1-84) for Hypoparathyroidism Reported at ASBMR Annual Meeting
|
|
14 Sep 2008 |
Transition Therapeutics Dose First Patient in Phase 2 Clinical Study of TT-223 in Type 2 Diabetes
|
|
11 Sep 2008 |
Zosano Pharma, Inc. Announces Positive Results of Phase 2 Trial With PTH Transdermal Patch in Osteoporosis
|
|
11 Sep 2008 |
Interesting new data on the effect of candesartan on diabetic eye complications
|
|
08 Sep 2008 |
XOMA 052 Clinical Results Support New Type 2 Diabetes Therapeutic Approach of Targeting Inflammatory Damage to Insulin-Producing Cells
|
|
08 Sep 2008 |
Biodel Announces Preliminary Results of Pivotal Phase III Clinical Trials for VIAject(TM)
|
|
08 Sep 2008 |
Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
|
|
08 Sep 2008 |
Saxagliptin Improved Key Measures of Glucose Control When Added to a Sulphonylurea or Thiazolidinedione in People With Inadequately Controlled Type 2 Diabetes
|
|
08 Sep 2008 |
Obecure Recruits First Patient in Phase II Obesity Study in Pre-Menopause Women
|
|
08 Sep 2008 |
ONGLYZA(TM) (saxagliptin) Demonstrated Significant Improvements Across Key Measures of Glucose Control When Added to a Sulfonylurea or Thiazolidinedione in People With Inadequately Controlled Type 2 Diabetes
|
|
08 Sep 2008 |
Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008
|
|
03 Sep 2008 |
Regeneron's ARCALYST(R) (rilonacept) Reduced Incidence of Gout Flares by 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-Lowering Therapy
|
|
03 Sep 2008 |
OSI Pharmaceuticals Initiates Clinical Development Program for Anti-Diabetes Candidate, PSN821
|
|
02 Sep 2008 |
ApoA-I Data Presented at European Society of Cardiology Congress
|
|
28 Aug 2008 |
Emerging diabetes drugs consider beta cell mass and function as an important target
|
|
27 Aug 2008 |
Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
|
|
25 Aug 2008 |
Phase 1b/2a Program Commences for RVX-208
|
|
24 Aug 2008 |
Telik Announces Diabestes License Agreement With Recetorbio
|
|
21 Aug 2008 |
Enobia Pharma initiates clinical testing of enzyme replacement therapy to treat Hypophosphatasia
|
|
21 Aug 2008 |
Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
|
|
21 Aug 2008 |
Activx Biosciences, Inc. Announces Positive Phase Ib and IIa Clinical Trial Results for KRP-104, a Flexible Dosing DPP-4 Inhibitor for Type 2 Diabetes
|
|
14 Aug 2008 |
Abbott and AstraZeneca expand relationship to include co-promotion of CRESTOR(R)
|
|
12 Aug 2008 |
Altus Pharmaceuticals Announces Achievement of Primary Endpoint in Phase 3 Efficacy Trial of Trizytek for Cystic Fibrosis Patients with Pancreatic Insufficiency
|
|
11 Aug 2008 |
DiaMedica Enrolls First Patient in Phase IIa Clinical Trial for DM-99
|
|
07 Aug 2008 |
Genzyme and Isis Begin Second Phase 3 Trial of Mipomersen
|
|
07 Aug 2008 |
Ore Pharmaceuticals Acquires Rights to Develop a Second Drug Candidate from Roche
|
|
06 Aug 2008 |
Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
|
| |
|
Results 51 - 100 of 1041 |
